Articles On Recce Pharmaceuticals (ASX:RCE)

A successful phase II clinical trial has taken place, assessing efficacy and safety of R327G in patients with acute bacterial skin and skin structure infections Recce said objectives exceeded with a 93% primary efficacy endpoint achieved f...

Recce Pharmaceuticals Ltd (ASX:RCE) has yielded positive data on the effectiveness of its topical gel in treating Acute Bacterial Skin and Skin Structure Infections, including patients with Diabetic Foot Infections, with a primary efficacy...

Dimerix forecasting second interim analysis of its ACTION3 phase III trial mid CY25 Retinal-diseases-focused biotech Opthea is awaiting two trial results in CY25 Recce set to start trial assessing topical gel to treat diabetic foot infecti...

The ASX200 has been up 0.5% at 8,445 points. Just after the local bourse opened, Trump says the U.S. is seriously considering tariffs on China due to the alleged production and distribution of fentanyl. IT has been the best performing...

ASX reverses after Trump’s tariff threat sends jitters Bitcoin drops as Trump’s policies remain unclear Hub24 shines, Santos slumps after project delay   After an upbeat start to the day, the S&P/ASX 200 Index, which had surged as muc...

Recce Pharmaceuticals Ltd (ASX:RCE) has seen its share price move up more than 1% on Tuesday’s news that the company successfully dosed all 30 participants in its Phase II clinical trial of a gel to treat skin infections. The trial – who...

RCE has dosed all patients in phase II trial of R327G treatment for skin infections Company says market valued at US$26bn globally Results pending ahead of planned phase III trial   Special Report: Recce Pharmaceuticals has wrapped up dos...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin Research reports on ASX-listed companies, to download in full. **** -Airtasker ((ART...

Stockhead’s Road to 2025 video series highlights companies’ key 2024 achievements and the routes they’re plotting towards a successful year ahead. In this episode, Sarah Hughan explores Recce Pharmaceuticals (ASX:RCE) and a series of succes...

Sydney-based Recce Pharmaceutical Ltd (ASX:RCE) has reached a landmark stage in its bid to commercialise a topical gel that would treat diabetic foot infections (DFIs), gaining approval for a Phase 3 trial in Indonesia to assess the gel in...

ASX drops as Trump’s tariff threat rattles markets Bluescope and Reece rise amid energy and bank sell-off EML Payments jumps after strong earnings report   The ASX closed in the red on Tuesday, down by 0.45% after being dragged down by a...

Recce Pharmaceuticals Ltd (ASX:RCE) has ticked off completion of all patents for two of its key anti-infectives, with the Australian Patent Office granting ‘Patent Family 3’ status to RECCE 327 (R327) and RECCE 529 (R529). The latest pat...

World Antimicrobial Resistance Awareness Week aims to put a spotlight on growing threat of antimicrobial resistance  Recce is tackling the global health problem of antibiotic-resistant superbugs with its new class of synthetic anti-infecti...

ASX up, Xero leads gains Miners hit as iron ore drops, Variscan jumps 50pc Asian stocks down, Bitcoin hits US$93k before retreating   Aussie shares climbed higher on Thursday, powered by a rally in tech companies and the big banks. At the...

Recce Pharmaceuticals (ASX:RCE) has received a $6.75 million Research and Development (R&D) Tax Incentive rebate from the Australian Taxation Office for FY24. This receipt was used to repay advances from Endpoints Capital reflectin...

ASX starts week lower with mining stocks under pressure Resolute mining plunges after CEO detained in Mali Bitcoin surges past US$81k as Trump’s win fuels optimism   The ASX had a rough start to the week, with mining stocks dragging the m...

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds. In this episode, host Sarah Hughan tells all on Recce Pharmaceuticals’ (ASX:RCE) approval from the Indonesian Government for a phase 3 clinical trial of i...

The ASX200 closed down 0.4% at 8,131 points. The Reserve Bank Board has kept interest rates on hold at 4.35% in line with consensus expectations. RBA Governor Michelle Bullock says the bank wants to be more convinced inflation is going t...

Aussie shares slip as RBA holds rates steady MinRes rebounds, Domino’s Don Meij quits Investors rethink Trump comeback as Harris leads in Iowa   Aussie shares slipped into the red on Tuesday, falling 0.4% as sentiment remained subdued aft...

Recce Pharmaceuticals is nearing completion in its Phase II clinical trial for acute bacterial skin and skin structure infections The study is designed to evaluate the efficacy of topical gel RECCE® 327 (R327G) It is designed to treat dia...

Non-DSMB unanimously agree Recce’s topical gel R327G is safe and well-tolerated in patients with acute bacterial skin and skin-structure infections R327G demonstrates highly encouraging efficacy results with all patients completing treatme...

  ASX closes  higher with consumer and utilities leading the charge Wall Street rally boosts sentiment as Nvidia jumps 4pc China’s CSI 300 index falls 5pc amid doubts over stimulus plans   The ASX closed 0.13% higher on Wednesday, thanks...

Recce Pharmaceuticals Ltd (ASX:RCE) has reached the halfway mark in dosing participants in its Phase II Acute Bacterial Skin and Skin Structure Infections (ABSSSI) clinical trial. The company has dosed 15 patients in the trial so far, wh...

Echo IQ shares soar after the FDA approves its aortic stenosis diagnosis. Pacific Edge’s cancer diagnostic revenues hold up despite US reimbursement doubts Recce Pharmaceuticals reaches halfway mark in phase II germ-busting trial   Health...

For those not regular watchers of the ASX biotech sector, it’s worth noting Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. Recce is developing its flagship patented next-gen anti-infective, R327, with clinical results so f...

Stockhead’s health and biotech expert Tim Boreham is back in the studio for another instalment of the Health Kick Podcast. In this episode, Tim chats with Recce Pharmaceuticals (ASX:RCE) managing director and CEO James Graham. Cracking the...

Southeast Asia presents growth for ASX health stocks with rising aging population and growing middle class EZZ has started selling EAORON branded products in Vietnam and signed Australian Open sponsorship deal  Recce has signed a MoU with...

Antimicrobial resistance is among the most significant threats to public health and development, says WHO Recce Pharmaceuticals is tackling the global health problem of antibiotic-resistant superbugs It has a military reconnaissance appro...

The ASX200 has hit a fresh all time high of 8,035 points in buoyant Monday trade with the market up 0.8% heading into 1pm. Investors are speculating the Federal Reserve in the United States could launch its rate cutting cycle with a 50 b...

Synthetic anti-infective developer Recce Pharmaceuticals Ltd (ASX:RCE) has made inroads for recognition of its RECCE® 327 Gel (or R327G) as a topical treatment for burn wound infections, gaining a US$2 million grant from the US Department o...

Keely Lynch: RCE Pharmaceuticals has announced a capital raise following the completion of its phase one and two UTI trial. To discuss this further, I’m joined by the company CEO, James Graham. Welcome James. It’s been a busy few weeks f...

IMM files a pre-IND application with US FDA for IMM-529 targeting common pathogen clostridioides difficile Ansell completes 100% acquisition of the assets of US giant Kimberly-Clark Corporation’s personal protective business Actinogen Xana...

Choppy day leaves the ASX 200 benchmark below zero, down -0.2pc Energy surges on news of a coal fire in Queensland, because that’s good for business everywhere else Small Caps winners’ list dominated by a $12 million boat sale by Wellard,...

The ASX200 closed the week up 0.1%. The IT sector finished on top, gaining 0.9%. Financials followed, gaining 0.75%. Materials took the hardest hit, falling just short of a percent. US Inflation The US will release its latest PCE i...

Sydney-based Recce Pharmaceuticals Ltd (ASX:RCE) has found that its synthetic anti-infective drug RECCE® 327 (or R327) is effective in treating bacterial growth – specifically Escherichia coli (E.coli) – following a Phase I/II clinical tria...

Microba completes program with  Ginkgo Bioworks Recce reports encouraging results from Phase I/II clinical trial Imricor completes second iCMR ablation procedure in Croatia   Microba Life Sciences (ASX:MAP) has announced the successful co...

Despite futures tipping a 0.25% decline on the bourse the market has tanked 1.10% in the first hour of trades. The immediate catalysts at play aren’t obvious but are likely being driven in part by low iron ore prices, stronger than expec...

The ASX200 is trading strongly to start the week, gaining around three quarters of a per cent. While the Real Estate sector has taken the lead, the Energy sector spurred early gains, driven by Strike Energy (ASX:STX), which is up more th...

Recce Pharma (ASX:RCE) has announced it’s further boosting its role as an emerging defence company operating in the US military supply chain. In April this year, the company notified the market it had started applying for a US defence re...

The work of pharmaceutical companies can bring new hope to patients delivering solutions to unmet medical needs. It can also turn a small market cap play into a giant – but it’s a process that’s not easy, it’s risky and it can take a lot of...

Recce Pharma (ASX:RCE) has announced the latest cohort of patients part of the company’s Phase I/II UTI trial has been dosed with the highest ever volume of R327 to date. In the ongoing IV-based trial that seeks to treat urinary tract in...

A pilot study testing the effectiveness of a synthetic drug to treat lung infections has yielded positive data for Australian-based Recce Pharmaceuticals Ltd (ASX:RCE). The efficacy of nebulised RECCE® 327 – also known as R327 – was test...

The ASX200 closed around 1.4 of a per cent up following the RBA’s decision to keep interest rates on hold. Interest rates were kept at 4.35%, in line with expectations from ING Bank analysts and others.  Today’s standout sectors were...

ASX rallies, with all sectors rallying on Tuesday The RBA holds rate, but keeps door open for more rate hikes Update on Bonza Airlines’ ongoing drama   The Aussie stock market rallied hard on Tuesday, up over +1%, as the RBA decided to ho...

The Reserve Bank of Australia has kept interest rates on hold at 4.35%, in line with expectations from ING Bank analysts and others.  A recent survey of economists showed only one of two dozen had called an RBA rate hike, despite concern...

Recce Pharmaceuticals (ASX:RCE) has confirmed its receipt of a patent in China to protect its class of anti-infective drugs. The China National Intellectual Property Administration (CNIPA) formally awarded the company a ‘Patent Family 2’...

ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month   The S&P/ASX 200 Health Care [XHJ] had a soft month in April...

The ASX200 is trading down around 1.1% with all eleven sectors in the red. Real-estate has fallen the most, down 1.86%, Industrials follow, shedding around 1.7%. Company News BHP BHP Group (ASX: BHP) has fallen 4.5% to $43.19. afte...

Recce Pharma cleared to increase R327’s minimum dose R327 can now be administered at 4,000mg over a fast infusion of 30 minutes ResMed has had a solid Q3   Recce Pharma cleared to increase drug dose Recce Pharmaceuticals (ASX:RCE) says an...

26 Apr 2024 - A snapshot of the stocks on the move, featuring Tamboran Resources (ASX:TBN), Recce Pharmaceuticals (ASX:RCE) and Cooper Metals (ASX:CPM).